Exhibit 99.1 Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, NJ (May 9, 2024) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovat ...